Dara Mbanze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dara Mbanze has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ana Gorgulho
Infectious Diseases Department, Unidade Local de Saúde de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal
2 shared publications - Cristóvão Figueiredo
Infectious Diseases Department, ULS Gaia e Espinho, Vila Nova de Gaia, Portugal
2 shared publications - Luís Malheiro
Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal
2 shared publications - Tiago Teixeira
Infectious Diseases Department, ULS Gaia e Espinho, Vila Nova de Gaia, Portugal
2 shared publications Ana Rita Paixão
School of Medicine, University of Minho, Braga, Portugal
1 shared publication- Ana Sofia Reis
Internal Medicine Department, ULS Gaia e Espinho, Vila Nova de Gaia, Portugal
1 shared publication
Latest Publications
- Open Access
- 19 August 2026
- Published by Springer Nature in Discover Medicine
- Vol. 3 (1) , 111
Epidemiology and predictors of 30-day mortality in clinically significant Clostridium species infections
Purpose: Clostridium species are an under-recognized cause of severe infections with substantial mortality, yet national data remain limited. This study aimed to characterize the epidemiological, microbiological, clinical, and therapeutic features of clinically significant Clostridium spp. infections and to identify factors associated with 30-day mortality. Methods: We conducted a retrospective, single-centre cohort study at Unidade Local de Saúde de Gaia-Espinho (Portugal), including all patients with clinically significant Clostridium spp. isolates between 1 January 2020 and 30 March 2025. Demographic, clinical, microbiological, and therapeutic data were obtained from electronic medical and laboratory records. The primary outcome was 30-day all-cause mortality. Survivors and non-survivors were compared using univariate and multivariable logistic regression analyses. Results: A total of 119 patients were included (median age 68.9 years). Most infections were community-acquired (73.1%), and C. perfringens was the most frequently identified species (58.8%). Thirty-day mortality was 22.7%. In univariate analysis, mortality was associated with older age, thrombocytopenia, hepatic and renal dysfunction, bacteremia, sepsis or septic shock, inadequate antimicrobial therapy, and lack of source control. In Firth penalised logistic regression, age (OR 1.09/year, 95% CI 1.04–1.16), hepatic dysfunction (OR 6.74, 95% CI 2.05–25.87), and septic shock (OR 56.41, 95% CI 11.11–458.37) were associated with mortality; adequate antimicrobial therapy was protective (OR 0.09, 95% CI 0.02–0.37). Conclusion: Clostridium spp. infections were associated with high mortality. Age and organ dysfunction were key risk factors, whereas early appropriate antimicrobial therapy was the main modifiable protective factor. Prompt recognition, timely antibiotics, and adequate source control are essential.
- 19 August 2026
- Published by Springer Nature in Discover Medicine
- Vol. 3 (1) , 111
Open AccessEpidemiology and predictors of 30-day mortality in clinically significant Clostridium species infections
Purpose: Clostridium species are an under-recognized cause of severe infections with substantial mortality, yet national data remain limited. This study aimed to characterize the epidemiological, microbiological, clinical, and therapeutic features of clinically significant Clostridium spp. infections and to identify factors associated with 30-day mortality. Methods: We conducted a retrospective, single-centre cohort study at Unidade Local de Saúde de Gaia-Espinho (Portugal), including all patients with clinically significant Clostridium spp. isolates between 1 January 2020 and 30 March 2025. Demographic, clinical, microbiological, and therapeutic data were obtained from electronic medical and laboratory records. The primary outcome was 30-day all-cause mortality. Survivors and non-survivors were compared using univariate and multivariable logistic regression analyses. Results: A total of 119 patients were included (median age 68.9 years). Most infections were community-acquired (73.1%), and C. perfringens was the most frequently identified species (58.8%). Thirty-day mortality was 22.7%. In univariate analysis, mortality was associated with older age, thrombocytopenia, hepatic and renal dysfunction, bacteremia, sepsis or septic shock, inadequate antimicrobial therapy, and lack of source control. In Firth penalised logistic regression, age (OR 1.09/year, 95% CI 1.04–1.16), hepatic dysfunction (OR 6.74, 95% CI 2.05–25.87), and septic shock (OR 56.41, 95% CI 11.11–458.37) were associated with mortality; adequate antimicrobial therapy was protective (OR 0.09, 95% CI 0.02–0.37). Conclusion: Clostridium spp. infections were associated with high mortality. Age and organ dysfunction were key risk factors, whereas early appropriate antimicrobial therapy was the main modifiable protective factor. Prompt recognition, timely antibiotics, and adequate source control are essential.
- Open Access
- 17 July 2026
- Published by Springer Nature in AIDS and Behavior
- p. 1-15
HIV-Related Stigma in People Living with HIV: A Cross-Sectional Analysis of a Portuguese Clinical Cohort
HIV-related stigma remains a barrier to well-being and long-term care despite effective antiretroviral therapy. We conducted a cross-sectional analysis using baseline data from a prospective real-world cohort of adults receiving routine HIV care in northern Portugal. Overall HIV stigma was the primary outcome, and associations with sociodemographic, clinical, laboratory, behavioral, and patient-reported variables were examined using univariable and multivariable linear regression. Among 467 participants, the median overall stigma score was 30 (Q1–Q3, 26–35), and disclosure concerns had the highest median subscale score. The multivariable model was statistically significant, F(7,429) = 10.254, p < 0.001, adjusted R² = 0.129. Higher overall stigma was independently associated with HIV-1 viral load ≥ 200 copies/mL (B = 4.489, 95% CI 0.660 to 8.318, t = 2.304, p = 0.022), anxiety symptoms (B = 0.318 per point, 95% CI 0.120 to 0.515, t = 3.166, p = 0.002), and depressive symptoms (B = 0.236 per point, 95% CI 0.031 to 0.441, t = 2.259, p = 0.024). A history of opportunistic infection was associated with lower stigma (B = -1.826, 95% CI -3.524 to -0.128, t = -2.114, p = 0.035). Higher quality-of-life scores were consistently associated with lower stigma (t values ranging from − 10.690 to -4.161, all p < 0.001). These findings support routine stigma-sensitive and psychologically informed HIV care to identify psychosocial needs and potentially improve well-being and treatment outcomes.
- 17 July 2026
- Published by Springer Nature in AIDS and Behavior
- p. 1-15
Open AccessHIV-Related Stigma in People Living with HIV: A Cross-Sectional Analysis of a Portuguese Clinical Cohort
HIV-related stigma remains a barrier to well-being and long-term care despite effective antiretroviral therapy. We conducted a cross-sectional analysis using baseline data from a prospective real-world cohort of adults receiving routine HIV care in northern Portugal. Overall HIV stigma was the primary outcome, and associations with sociodemographic, clinical, laboratory, behavioral, and patient-reported variables were examined using univariable and multivariable linear regression. Among 467 participants, the median overall stigma score was 30 (Q1–Q3, 26–35), and disclosure concerns had the highest median subscale score. The multivariable model was statistically significant, F(7,429) = 10.254, p < 0.001, adjusted R² = 0.129. Higher overall stigma was independently associated with HIV-1 viral load ≥ 200 copies/mL (B = 4.489, 95% CI 0.660 to 8.318, t = 2.304, p = 0.022), anxiety symptoms (B = 0.318 per point, 95% CI 0.120 to 0.515, t = 3.166, p = 0.002), and depressive symptoms (B = 0.236 per point, 95% CI 0.031 to 0.441, t = 2.259, p = 0.024). A history of opportunistic infection was associated with lower stigma (B = -1.826, 95% CI -3.524 to -0.128, t = -2.114, p = 0.035). Higher quality-of-life scores were consistently associated with lower stigma (t values ranging from − 10.690 to -4.161, all p < 0.001). These findings support routine stigma-sensitive and psychologically informed HIV care to identify psychosocial needs and potentially improve well-being and treatment outcomes.